United States · Exchanges & live quotes · Nasdaq

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

Published by Nasdaq · United States 2 h ago

(RTTNews) - Gilead Sciences, Inc. (GILD), a biopharmaceutical company, announced that it has reached an agreement to acquire investigational oral IL-23R inhibitor program,…

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

OilPrice.com

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

Share

Also worth reading

Eni's Profits Soar 125% as Refining Boom Fuels Massive Investor Payouts

Injective (INJ) Drops 8.9% Amid Broad Crypto Selloff

Gen Z Is Starting Businesses at a Record Pace. Here’s How

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog